Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICEBERG 1: Olaparib in Advanced BRCA-associated Breast Cancer
NCT00494234Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2007
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label trial of olaparib in breast cancer (2 arms), sponsored by AstraZeneca. Primary endpoint: Objective Response Rate up to 2 years. Started Jun 2007; status: completed.
02
Drugs
olaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00494234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00494234.